# Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

> **NCT06203912** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Elvira Umyarova** · enrollment: 3 (actual)

## Conditions studied

- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone
- **PROCEDURE:** Echocardiography
- **BIOLOGICAL:** Isatuximab
- **OTHER:** Questionnaire Administration
- **BIOLOGICAL:** Universal Donor Expanded TGF-beta-imprinted NK Cells

## Key facts

- **NCT ID:** NCT06203912
- **Lead sponsor:** Elvira Umyarova
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-05
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06203912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06203912, "Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06203912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*